The FDA has approved a new, under-the-skin injection called semaglutide for weight loss.
That’s according to Medscape.
Semaglutide induces weight loss by reducing hunger, increasing feelings of fullness, and thereby helping people eat less and reduce their calorie intake
Novo Nordisk company announcement
The drug will be sold in the U.S. as “Wegovy.”
According to the maker, Novo Nordisk, Wegovy is a “subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for chronic weight management…The potential indication is for the treatment of adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity.”
Physicians and obese Americans have long sought a safe and effective way to melt pounds.
Many weight loss products have been FDA approved, only to later be removed from the market for safety reasons.
“Fen-phen” was linked to heart valve damage. Approximately 175,000 claims were filed against the maker, Wyeth, which set aside $21 billion to settle the lawsuits, according Bloomberg news.
Meridia was removed from the market in October 2010 because it caused heart problems and strokes.
The drug Belviq was pulled from market over an increased cancer risk.
According to the FDA: “FDA has issued over 30 public notifications and recalled 7 tainted weight loss products in 2014. The agency also has issued warning letters, seized products, and criminally prosecuted people responsible for marketing these illegal diet products. In addition, FDA maintains an online list of tainted weight-loss products.”
The FDA adds:
“To help people with long-term weight management, FDA has approved prescription drugs such as Belviq, Qysmia, and Contrave, but these products are intended for people at least 18 years of age who:
- have a body mass index (BMI, a standard measure of body fat) of 30 or greater (considered obese); or
- have a BMI of 27 or greater (considered overweight) and have at least one other weight-related health condition.
Moreover, if you are going to embark on any type of weight control campaign, you should talk to your health care professional about it first.”
Read more from the company at the link below:
https://ml-eu.globenewswire.com/Resource/Download/7886cc75-b321-4f2b-9355-6fb602d0075a
Fight government overreach. Support free speech and free press. Donate to Attkisson v. DOJ here.
